Filana Therapeutics Q2 FY26 net loss narrows 80.55% to $8.6 million - FLNA News | RalliesFilana Therapeutics Q2 FY26 net loss narrows 80.55% to $8.6 million
F
FLNA• Q2 FY26 results
- Filana Therapeutics posted a GAAP net loss of $8.6 million, or $0.18 per share, in Q2 2026, narrowing from $44.2 million.
- R&D expense fell 35% to $3.3 million, due primarily to the phase-out of its Alzheimer’s disease program completed in Q2 2025.
- G&A expense dropped 85% to $6.1 million, due primarily to a $31.25 million securities litigation loss contingency recorded in Q2 2025.
Clinical hold update
- Management said it is engaging with the FDA to address the clinical hold on its TSC-related epilepsy proof-of-concept trial.
- Unrestricted year-end cash is guided at $36 million to $40 million.
Cash position and debt
- Cash and cash equivalents totaled $82.7 million at June 30, 2026.
- The company reported no debt.
TXT
•
